Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention and Treatment of Episodic Migraine by Cabergoline Therapy (PROTECT). A Randomized, Placebo-controlled, Double-blind, Investigator-initiated Trial

NCT07072910 is registered in ClinicalTrials.gov with Aarhus University Hospital as lead sponsor.

NCT NCT07072910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07072910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention and Treatment of Episodic Migraine by Cabergoline Therapy (PROTECT). A Randomized, Placebo-controlled, Double-blind, Investigator-initiated Trial
Lead sponsor
Aarhus University Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 12, 2025
Completion date
September 1, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

migraine